Differentiating systemic lupus erythematosus from other diseases: Difference between revisions

	Systemic lupus erythematosus Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Systemic lupus erythematosus from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Lupus and Quality of Life
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Differentiating systemic lupus erythematosus from other diseases On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Differentiating systemic lupus erythematosus from other diseases All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
National Guidelines Clearinghouse
NICE Guidance
FDA on Differentiating systemic lupus erythematosus from other diseases
on Differentiating systemic lupus erythematosus from other diseases
Differentiating systemic lupus erythematosus from other diseases in the news
Blogs onDifferentiating systemic lupus erythematosus from other diseases
Directions to Hospitals Treating Systemic lupus erythematosus
Risk calculators and risk factors for Differentiating systemic lupus erythematosus from other diseases

← Older edit Newer edit →

VisualWikitext

Revision as of 19:28, 11 July 2017

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahshid Mir, M.D. [2]

Overview

Systemic lupus erythematosus (SLE) must be differentiated from other diseases that cause skin rash, arthritis, positive autoimmune serology, weight loss, fevers and chronic pain, such as rheumatoid arthritis(RA), mixed connective tissue disease (MCTD), systemic sclerosis (SSc), dermatomyositis (DM), polymyositis(PM), and other autoimmune diseases.

Differentiating systemic lupus erythematosus from other diseases

Systemic lupus erythematosus (SLE) must be differentiated from other diseases that cause skin rash, arthritis, positive autoimmune serology, weight loss, fevers and chronic pain, such as rheumatoid arthritis(RA), mixed connective tissue disease (MCTD), systemic sclerosis (SSc), dermatomyositis (DM), polymyositis(PM), and other autoimmune diseases.

Differetiating SLE from other diseases that cause arthritis and rash

n		Arthritis					Auto-antibodies							Raynaud phenamon	Rash pattern	Distinguishing/specific features
n		Polyarthritis	Tenderness	Edema	Deformity /Erosion	Pattern	ANA	RF	Anti-CCp	anti U1RNP	AntiSm	AntiRo	Anti-dsDNA	Raynaud phenamon	Rash pattern	Distinguishing/specific features
Systemic lupus erythematosus						Small joints
Rheumatoid arthritis (RA)		+	+	+	+	Small and large joints		↑↑	↑↑					+
Rhupus		+	+	+	+	Small and large joints	↑	↑	↑	↑	↑		↑	+	Patients with overlapping features of both SLE and RA Serologies consistent with both SLE and RA	Erosive arthropathy that is atypical for SLE
Mixed connective tissue disease (MCTD)^[1]					+	Small and large joints		↑↑	↑					+	A mix disease with overlapping features of SLE, systemic sclerosis (SSc), and polymyositis (PM) Antibodies against U1 ribonucleoprotein (RNP)
Undifferentiated connective tissue disease (UCTD)		+				Small and large joints	↑	↑			↑			+	erythematous macules, patches, or papules with delicate scale mostly in lower extremities	sclerodactyly telangiectasias calcinosis malignant hypertension acute renal failure
Systemic sclerosis (SSc)		+/-	+	+	+/-		↑↑				↑		↑	+	skin thickening and hardening Edematous swelling and erythema	Sclerodactyly Telangiectasias Calcinosis Malignant hypertension acute renal failure
Sjögren’s syndrome 15485020		+/-	+/-			Lower extremity and axiallary creases	↑					↑			Xerosis Scaly skin Annular erythema	Keratoconjunctivitis sicca Xerostomia
Vasculitis	Giant cell		+	+											Rare	cranial branches of arteries visual loss
	Takayasu		+/-	+/-											Erythema nodosum Pyoderma gangrenosum
	Poly-arteritis nodosa		+/-												tender erythematous nodules Purpura Livedo reticularis Bullous or vesicular eruption
Behçet’s syndrome		+/-	+/-	+/-											acneiform lesions Papulo-vesiculo-pustular eruptions Superficial thrombophlebitis	Male dominancy ANA-negative
Kikuchi’s disease			+/-				↑/↓								Transient skin rashes Malar rash Erythematous macules, patches, papules, or plaques	May be associated with SLE
Serum sickness		+/-	+	+/-											pruritic rash urticarial and/or serpiginous macular rash	Negative ANA Self-limited
Psoriatic arthritis						Small and large joints
Human parvovirus B19 infection		+	+			Small joints										Flu-like symptoms Hematologic abnormalities such as leukopenia and thrombocytopenia

References

↑ Cappelli S, Bellando Randone S, Martinović D, Tamas MM, Pasalić K, Allanore Y, Mosca M, Talarico R, Opris D, Kiss CG, Tausche AK, Cardarelli S, Riccieri V, Koneva O, Cuomo G, Becker MO, Sulli A, Guiducci S, Radić M, Bombardieri S, Aringer M, Cozzi F, Valesini G, Ananyeva L, Valentini G, Riemekasten G, Cutolo M, Ionescu R, Czirják L, Damjanov N, Rednic S, Matucci Cerinic M (2012). ""To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity". Semin. Arthritis Rheum. 41 (4): 589–98. doi:10.1016/j.semarthrit.2011.07.010. PMID 21959290.

[pmid21959290-1] Cappelli S, Bellando Randone S, Martinović D, Tamas MM, Pasalić K, Allanore Y, Mosca M, Talarico R, Opris D, Kiss CG, Tausche AK, Cardarelli S, Riccieri V, Koneva O, Cuomo G, Becker MO, Sulli A, Guiducci S, Radić M, Bombardieri S, Aringer M, Cozzi F, Valesini G, Ananyeva L, Valentini G, Riemekasten G, Cutolo M, Ionescu R, Czirják L, Damjanov N, Rednic S, Matucci Cerinic M (2012). ""To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity". Semin. Arthritis Rheum. 41 (4): 589–98. doi:10.1016/j.semarthrit.2011.07.010. PMID 21959290.

[1]

@@ Line 32: / Line 32: @@
 ! align="center" style="background:#4479BA; color: #FFFFFF;" |Anti-dsDNA
 |-
-| colspan="2" |[[Systemic lupus erythematosus]]
+| colspan="2"  align="center" style="background:#DCDCDC;" |[[Systemic lupus erythematosus]]
 |
 |
@@ Line 49: / Line 49: @@
 |
 |-
-| colspan="2" |[[Rheumatoid arthritis]] ([[Rheumatoid arthritis|RA]])
+| colspan="2"  align="center" style="background:#DCDCDC;" |[[Rheumatoid arthritis]] ([[Rheumatoid arthritis|RA]])
 | +
 | +
@@ Line 68: / Line 68: @@
 *
 |-
-| colspan="2" |Rhupus
+| colspan="2"  align="center" style="background:#DCDCDC;" |Rhupus
 | +
 | +
@@ Line 88: / Line 88: @@
 * Erosive [[arthropathy]] that is atypical for SLE
 |-
-| colspan="2" |[[Mixed connective tissue disease]] (MCTD)<ref name="pmid21959290">{{cite journal |vauthors=Cappelli S, Bellando Randone S, Martinović D, Tamas MM, Pasalić K, Allanore Y, Mosca M, Talarico R, Opris D, Kiss CG, Tausche AK, Cardarelli S, Riccieri V, Koneva O, Cuomo G, Becker MO, Sulli A, Guiducci S, Radić M, Bombardieri S, Aringer M, Cozzi F, Valesini G, Ananyeva L, Valentini G, Riemekasten G, Cutolo M, Ionescu R, Czirják L, Damjanov N, Rednic S, Matucci Cerinic M |title="To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity |journal=Semin. Arthritis Rheum. |volume=41 |issue=4 |pages=589–98 |year=2012 |pmid=21959290 |doi=10.1016/j.semarthrit.2011.07.010 |url=}}</ref>
+| colspan="2"  align="center" style="background:#DCDCDC;" |[[Mixed connective tissue disease]] (MCTD)<ref name="pmid21959290">{{cite journal |vauthors=Cappelli S, Bellando Randone S, Martinović D, Tamas MM, Pasalić K, Allanore Y, Mosca M, Talarico R, Opris D, Kiss CG, Tausche AK, Cardarelli S, Riccieri V, Koneva O, Cuomo G, Becker MO, Sulli A, Guiducci S, Radić M, Bombardieri S, Aringer M, Cozzi F, Valesini G, Ananyeva L, Valentini G, Riemekasten G, Cutolo M, Ionescu R, Czirják L, Damjanov N, Rednic S, Matucci Cerinic M |title="To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity |journal=Semin. Arthritis Rheum. |volume=41 |issue=4 |pages=589–98 |year=2012 |pmid=21959290 |doi=10.1016/j.semarthrit.2011.07.010 |url=}}</ref>
 |
 |
@@ Line 108: / Line 108: @@
 *
 |-
-| colspan="2" |[[Undifferentiated connective tissue disease]] (UCTD)
+| colspan="2"  align="center" style="background:#DCDCDC;" |[[Undifferentiated connective tissue disease]] (UCTD)
 | +
 |
@@ Line 132: / Line 132: @@
 * acute renal failure
 |-
-| colspan="2" |[[Systemic sclerosis]] (SSc)
+| colspan="2"  align="center" style="background:#DCDCDC;" |[[Systemic sclerosis]] (SSc)
 |<nowiki>+/-</nowiki>
 |<nowiki>+</nowiki>
@@ Line 156: / Line 156: @@
 * [[acute renal failure]]
 |-
-| colspan="2" |Sjögren’s syndrome
+| colspan="2"  align="center" style="background:#DCDCDC;" |Sjögren’s syndrome
 15485020
 |<nowiki>+/-</nowiki>
@@ Line 183: / Line 183: @@
 * [[Xerostomia]]
 |-
-| rowspan="3" |Vasculitis
+| rowspan="3"  align="center" style="background:#DCDCDC;" |Vasculitis
-|Giant cell
+| align="center" style="background:#DCDCDC;" |Giant cell
 |
 |<nowiki>+</nowiki>
@@ Line 197: / Line 197: @@
 |
 |
-| rowspan="3" |
+| rowspan="3"|
 |
 * Rare
@@ Line 204: / Line 204: @@
 * visual loss
 |-
-|[[Takayasu's arteritis|Takayasu]]
+| align="center" style="background:#DCDCDC;" |[[Takayasu's arteritis|Takayasu]]
 |
 | +/-
@@ Line 222: / Line 222: @@
 |
 |-
-|[[Polyarteritis nodosa|Poly-arteritis nodosa]]
+| align="center" style="background:#DCDCDC;" |[[Polyarteritis nodosa|Poly-arteritis nodosa]]
 |
 | +/-
@@ Line 242: / Line 242: @@
 |
 |-
-| colspan="2" |Behçet’s syndrome
+| colspan="2"  align="center" style="background:#DCDCDC;" |Behçet’s syndrome
 |<nowiki>+/-</nowiki>
 |<nowiki>+/-</nowiki>
@@ Line 264: / Line 264: @@
 * [[ANA]]-negative
 |-
-| colspan="2" |Kikuchi’s disease
+| colspan="2"  align="center" style="background:#DCDCDC;" |Kikuchi’s disease
 |
 |<nowiki>+/-</nowiki>
@@ Line 286: / Line 286: @@
 * May be associated with SLE
 |-
-| colspan="2" |Serum sickness
+| colspan="2"  align="center" style="background:#DCDCDC;" |Serum sickness
 |<nowiki>+/-</nowiki>
 |<nowiki>+</nowiki>
@@ Line 307: / Line 307: @@
 * Self-limited
 |-
-| colspan="2" |Psoriatic arthritis
+| colspan="2"  align="center" style="background:#DCDCDC;" |Psoriatic arthritis
 |
 |
@@ Line 324: / Line 324: @@
 |
 |-
-| colspan="2" |Human [[parvovirus]] B19 infection
+| colspan="2"  align="center" style="background:#DCDCDC;" |Human [[parvovirus]] B19 infection
 |<nowiki>+</nowiki>
 |<nowiki>+</nowiki>